Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Just saw Johnson & Johnson got approval backing for AKEEGA in Europe - pretty significant for metastatic prostate cancer patients with BRCA1/2 mutations. The combo drug (niraparib plus abiraterone acetate) showed solid results in their Phase 3 AMPLITUDE trial with 696 patients. The data showed real improvements in progression-free survival compared to placebo, which is what they were testing for. What's interesting is the BRCA1 mutation angle - feels like precision medicine is really starting to matter in oncology. The EMA's CHMP committee recommended the indication extension, so this could actually reach patients pretty soon. Not sure how many people actually know about BRCA1 testing for prostate cancer though. Anyway, good to see progress on treatments that target specific genetic markers like BRCA1/2.